← Leaderboards
Tristram D Bahnson
Duke University
$1,370,084
Attributed
$1,370,084
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,370,084 · 2
By mechanism
M01$1,370,084 · 2
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Kenneth G. Manton$25,808,973
- James W. Vaupel$19,203,791
- Edward L Pritchett$2,014,219
- Elizabeth J Costello$23,289,605
- James A. Blumenthal$36,599,112
Others in their field
Top investigators on “Antiarrhythmic Agent”
- Dan M Roden · Vanderbilt University Medical Center$19,264,996
- Bjorn C Knollmann · Georgetown University$9,877,947
- Dawood Darbar · University Of Illinois At Chicago$8,481,255
- Bruce M Psaty · University Of Washington$5,374,998
- Michael R. Rosen · Columbia University Health Sciences$5,251,596
- Jeffrey Nicholas Johnston · Indiana University Bloomington$3,861,930
Research focus
Antiarrhythmic AgentAtrial FibrillationClinical ResearchHeart Disorder ChemotherapyHuman SubjectHuman Therapy EvaluationTachycardiaLongitudinal Human StudyHuman Old Age (65+)Drug Administration Rate /DurationImidazole
Grant awards (11)
PH III: AZIMILIDE LONG TERM TREATMENT$117,022
M01 · FY2002 · RR
PH III: AZIMILIDE CONTROLLED TRIAL$117,022
M01 · FY2002 · RR
PH III: AZIMILIDE LONG TERM TREATMENT$293,069
M01 · FY2001 · RR
PH III: AZIMILIDE CONTROLLED TRIAL$293,069
M01 · FY2001 · RR
PH III: AZIMILIDE CONTROLLED TRIAL$117,022
M01 · FY2001 · RR
PH III: AZIMILIDE CONTROLLED TRIAL$117,022
M01 · FY2001 · RR
PH III: AZIMILIDE LONG TERM TREATMENT$117,022
M01 · FY2001 · RR
PH III: AZIMILIDE LONG TERM TREATMENT$117,022
M01 · FY2001 · RR
PH III: AZIMILIDE CONTROLLED TRIAL$40,907
M01 · FY2000 · RR
PH III: AZIMILIDE LONG TERM TREATMENT$40,907
M01 · FY2000 · RR
PH III: AZIMILIDE LONG TERM TREATMENT$0
M01 · FY2000 · RR